A Phase 1 Study to Assess the Safety of NLY01 in Healthy Subjects
Status:
Completed
Trial end date:
2019-07-30
Target enrollment:
Participant gender:
Summary
This is a Phase 1, first-in-human study designed to assess the safety, tolerability, and
pharmacokinetics of NLY01, a PEGylated form of exenatide, in healthy volunteers. NLY01 is
being developed as a potential treatment for neurodegenerative disorders including
Parkinson's disease. This study is intended to identify the appropriate dose-range for
evaluation in Parkinson's disease patients.